Out-of-pocket costs for direct oral anticoagulants and prescription abandonment among patients with nonvalvular atrial fibrillation or venous thromboembolism
Among patients with NVAF or VTE, OOP costs of the first DOAC claim greater than or equal to $100 were associated with the highest risk of abandoning the first DOAC prescription.
Authors
- Maryia Zhdanava (ORCID: https://orcid.org/0000-0002-7995-2578)
- Jill Korsiak (ORCID: https://orcid.org/0000-0002-7509-4553)
- Mark J. Alberts (ORCID: https://orcid.org/0000-0001-5488-6810)
- Veronica Ashton (ORCID: https://orcid.org/0000-0003-4880-1897)
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
- Fengyi Jiang
Institutions
- Hartford Hospital (US)
- Johnson & Johnson (United States) (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-03-28
- DOI
- https://doi.org/10.18553/jmcp.2025.31.4.366
- Citations
- 3
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.16